Erratum to: The Combination of Insulin-Like Growth Factor Receptor 1 (IGF1R) Antibody Cixutumumab and Mitotane as a First-Line Therapy for Patients with Recurrent/Metastatic Adrenocortical Carcinoma: a Multi-institutional NCI-Sponsored Trial

Antonio M. Lerario · Francis P. Worden · Carole A. Ramm · Elizabeth A. Hesseltnine ·
Walter M. Stadler · Tobias Else · Manisha H. Shah · Edem Agamah · Krishna Rao ·
Gary D. Hammer

Published online: 6 September 2014
© Springer Science+Business Media New York 2014

Erratum to: Horm Canc
DOI 10.1007/s12672-014-0182-1

The last name of the fourth author was misspelled as Elizabeth A. Hasseltine in the original publication. The correct spelling of her name is **Elizabeth A Hesseltnine**.

The authors apologize for this error.

The online version of the original article can be found at <http://dx.doi.org/10.1007/s12672-014-0182-1>.

A. M. Lerario · C. A. Ramm · E. A. Hesseltnine · T. Else ·
G. D. Hammer (✉)
Division of Metabolism, Endocrinology & Diabetes, Medical
School, University of Michigan, 109 Zina Pitcher Place, 1528 BSRB,
Ann Arbor, MI 48109, USA
e-mail: ghammer@med.umich.edu

F. P. Worden
Division of Hematology/Oncology, University of Michigan, 1500 E
Medical Center Dr, C343 MIB, SPC 5848, Ann Arbor, MI 48109,
USA

W. M. Stadler
Division of Hematology/Oncology, University of Chicago, 5841 S
Maryland Ave Mc2115, Chicago, IL 60637, USA

M. H. Shah
Ohio State University Comprehensive Cancer Center, 320 W 10th
Avenue, 4th Floor Starling Loving Hall, Columbus, OH 43210, USA

E. Agamah
IHDN—International Health and Development Network, 2050 W
Iles Ave, Springfield, IL 62704, USA

K. Rao
Division of Hematology/Medical Oncology, Department of Internal
Medicine and Simmons Cancer Institute, Southern Illinois University
School of Medicine, 315 West Carpenter, 1st Floor, Clinic B,
Springfield, IL 62702, USA